Index RUT
P/E -
EPS (ttm) -1.65
Insider Own 13.11%
Shs Outstand 92.38M
Perf Week -7.83%
Market Cap 98.58M
Forward P/E -
EPS next Y -2.28
Insider Trans 0.06%
Shs Float 78.68M
Perf Month -19.70%
Income -149.10M
PEG -
EPS next Q -0.45
Inst Own 60.34%
Short Float 12.99%
Perf Quarter -50.23%
Sales 9.99M
P/S 9.87
EPS this Y -16.21%
Inst Trans 3.94%
Short Ratio 7.65
Perf Half Y -39.94%
Book/sh 2.74
P/B 0.39
EPS next Y -19.08%
ROA -39.14%
Short Interest 10.22M
Perf Year -85.71%
Cash/sh 2.25
P/C 0.47
EPS next 5Y -22.05%
ROE -47.99%
52W Range 1.01 - 7.24
Perf YTD -33.33%
Dividend Est. -
P/FCF -
EPS past 5Y -33.41%
ROI -53.63%
52W High -85.36%
Beta 2.26
Dividend TTM -
Quick Ratio 7.16
Sales past 5Y 42.68%
Gross Margin 60.71%
52W Low 4.74%
ATR (14) 0.09
Dividend Ex-Date -
Current Ratio 7.16
EPS Y/Y TTM -14.04%
Oper. Margin -1667.16%
RSI (14) 30.74
Volatility 7.49% 7.45%
Employees 147
Debt/Eq 0.10
Sales Y/Y TTM -71.01%
Profit Margin -1491.95%
Recom 1.40
Target Price 13.80
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q 0.23%
Payout -
Rel Volume 0.48
Prev Close 1.07
Sales Surprise -1.39%
EPS Surprise 6.59%
Sales Q/Q -41.62%
Earnings Mar 10 AMC
Avg Volume 1.34M
Price 1.06
SMA20 -13.27%
SMA50 -24.49%
SMA200 -43.91%
Trades
Volume 637,800
Change -0.93%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-03-24 Downgrade
Evercore ISI
Outperform → In-line
$13 → $3
Nov-08-23 Initiated
Cantor Fitzgerald
Neutral
Oct-31-23 Initiated
Evercore ISI
Outperform
$13
Jul-11-23 Initiated
Truist
Buy
$23
Feb-18-22 Initiated
RBC Capital Mkts
Outperform
$22
Dec-01-21 Initiated
Oppenheimer
Outperform
$36
Nov-30-21 Initiated
H.C. Wainwright
Buy
$28
Nov-15-21 Upgrade
Citigroup
Neutral → Buy
$27
Aug-17-21 Initiated
SVB Leerink
Outperform
$32
Aug-17-21 Initiated
Citigroup
Neutral
$27
Aug-17-21 Initiated
BofA Securities
Buy
$30
Show Previous Ratings
Mar-10-25 05:15PM
04:05PM
Feb-18-25 04:05PM
05:45AM
Feb-07-25 05:45AM
05:45AM
Loading…
Jan-31-25 05:45AM
Jan-24-25 05:45AM
Jan-17-25 05:45AM
Jan-14-25 05:45AM
Jan-12-25 07:05PM
Jan-07-25 04:00PM
Jan-02-25 08:00AM
Dec-30-24 03:01PM
Dec-16-24 09:55AM
Nov-20-24 04:00PM
06:05PM
Loading…
Nov-06-24 06:05PM
04:05PM
Oct-31-24 03:53AM
Oct-17-24 03:06PM
Sep-25-24 09:00AM
Sep-03-24 08:00AM
Aug-26-24 04:00PM
Aug-12-24 08:00AM
Aug-06-24 06:50PM
04:05PM
10:00AM
Jul-17-24 07:45AM
Jul-09-24 08:00AM
Jun-02-24 07:00PM
May-30-24 04:01PM
04:00PM
Loading…
May-12-24 04:00PM
May-09-24 05:23AM
May-07-24 10:55PM
05:25PM
04:05PM
May-01-24 04:05PM
Apr-27-24 06:00AM
Apr-24-24 10:00AM
Apr-15-24 09:00AM
Apr-04-24 04:00PM
Mar-14-24 12:00PM
Mar-13-24 03:32PM
Mar-12-24 12:37PM
Mar-11-24 04:05PM
Mar-05-24 04:30PM
Feb-26-24 01:14PM
06:45AM
Feb-23-24 11:25PM
Feb-15-24 04:05PM
Feb-12-24 08:30AM
Jan-15-24 08:45AM
Jan-07-24 11:00AM
Dec-13-23 07:26AM
05:20AM
Dec-12-23 04:02PM
Dec-08-23 12:00PM
Dec-06-23 09:55AM
Nov-20-23 09:55AM
Nov-07-23 04:00PM
Nov-06-23 08:00AM
Nov-01-23 04:05PM
Oct-20-23 05:00AM
Oct-18-23 08:00AM
Oct-11-23 06:00AM
Oct-10-23 05:40AM
Oct-05-23 10:07AM
Sep-27-23 08:30AM
08:00AM
Sep-23-23 08:45AM
Aug-29-23 04:00PM
Aug-24-23 05:58AM
Aug-15-23 04:08PM
03:08PM
Aug-08-23 05:15PM
04:00PM
Jul-28-23 08:30AM
Jul-22-23 09:45AM
Jul-21-23 10:00AM
Jul-20-23 11:35AM
Jul-19-23 09:30AM
Jul-17-23 05:03PM
Jul-14-23 11:27AM
Jul-13-23 11:15PM
04:03PM
04:01PM
04:01PM
09:30AM
Jul-12-23 09:40AM
Jul-11-23 09:55AM
Jul-07-23 08:14AM
Jul-06-23 11:03PM
01:56PM
11:54AM
10:43AM
08:00AM
Jun-15-23 12:53PM
May-31-23 04:00PM
May-16-23 11:25AM
May-09-23 05:15PM
04:00PM
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MCCLUNG BARBARA G Chief Legal Officer Feb 21 '25 Sale 1.35 3,564 4,811 443,502 Feb 21 08:19 PM Khan Ruhi Ahmad Chief Business Officer Feb 21 '25 Sale 1.35 3,564 4,811 66,936 Feb 21 08:19 PM Kanner Steven Chief Scientific Officer Feb 21 '25 Sale 1.35 3,564 4,811 431,556 Feb 21 08:18 PM Ryali Sriram Chief Financial Officer Jan 29 '25 Buy 1.42 17,360 24,651 17,360 Jan 30 04:02 PM
Index RUT
P/E -
EPS (ttm) -0.90
Insider Own 2.74%
Shs Outstand 81.85M
Perf Week 1.10%
Market Cap 228.63M
Forward P/E -
EPS next Y -0.56
Insider Trans 374.12%
Shs Float 80.57M
Perf Month -33.97%
Income -65.28M
PEG -
EPS next Q -0.24
Inst Own 78.09%
Short Float 3.76%
Perf Quarter -41.65%
Sales 59.34M
P/S 3.85
EPS this Y 17.04%
Inst Trans 2.13%
Short Ratio 3.73
Perf Half Y 5.34%
Book/sh 0.82
P/B 3.38
EPS next Y 23.81%
ROA -45.72%
Short Interest 3.03M
Perf Year -20.46%
Cash/sh 0.89
P/C 3.09
EPS next 5Y 31.19%
ROE -85.03%
52W Range 2.47 - 6.08
Perf YTD -42.14%
Dividend Est. -
P/FCF -
EPS past 5Y -33.31%
ROI -52.64%
52W High -54.61%
Beta 2.33
Dividend TTM -
Quick Ratio 4.10
Sales past 5Y 4.02%
Gross Margin 64.39%
52W Low 11.74%
ATR (14) 0.29
Dividend Ex-Date -
Current Ratio 4.18
EPS Y/Y TTM 19.42%
Oper. Margin -98.33%
RSI (14) 27.82
Volatility 8.21% 8.03%
Employees 188
Debt/Eq 0.89
Sales Y/Y TTM -15.39%
Profit Margin -109.99%
Recom 1.57
Target Price 7.33
Option/Short Yes / Yes
LT Debt/Eq 0.85
EPS Q/Q -23.29%
Payout -
Rel Volume 1.00
Prev Close 2.76
Sales Surprise -21.71%
EPS Surprise -258.13%
Sales Q/Q -19.20%
Earnings Feb 27 AMC
Avg Volume 812.60K
Price 2.76
SMA20 -21.91%
SMA50 -34.61%
SMA200 -25.19%
Trades
Volume 816,023
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-19-24 Downgrade
The Benchmark Company
Buy → Hold
Jun-03-24 Resumed
Jefferies
Buy
$5
May-30-24 Initiated
Cantor Fitzgerald
Overweight
$11
Feb-29-24 Upgrade
The Benchmark Company
Hold → Buy
Nov-07-23 Downgrade
The Benchmark Company
Buy → Hold
Aug-07-23 Downgrade
TD Cowen
Outperform → Market Perform
$21 → $4
May-09-23 Downgrade
H.C. Wainwright
Buy → Neutral
Mar-31-22 Resumed
Piper Sandler
Overweight
$35
Mar-02-22 Resumed
Cowen
Outperform
Apr-12-21 Initiated
Piper Sandler
Overweight
$32
Mar-01-21 Initiated
Stifel
Buy
$30
Feb-26-21 Reiterated
H.C. Wainwright
Buy
$21 → $26
Mar-10-20 Initiated
The Benchmark Company
Buy
Jan-17-19 Upgrade
First Analysis Sec
Neutral → Outperform
$12 → $19
May-16-18 Initiated
Stephens
Overweight
$16
Oct-13-17 Reiterated
H.C. Wainwright
Buy
$8 → $8.50
May-31-17 Initiated
Jefferies
Buy
$8
Jan-26-17 Downgrade
First Analysis Sec
Overweight → Equal-Weight
$5.50
Jan-04-17 Upgrade
Ladenburg Thalmann
Neutral → Buy
Jan-06-16 Initiated
H.C. Wainwright
Buy
$6
Show Previous Ratings
Mar-07-25 04:05PM
Feb-28-25 11:02AM
(Thomson Reuters StreetEvents) -22.65%
02:36AM
Feb-27-25 06:35PM
05:36PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
Feb-18-25 04:05PM
Feb-14-25 05:15PM
Feb-13-25 04:05PM
Feb-06-25 04:05PM
Jan-16-25 04:05PM
Jan-10-25 04:05PM
Dec-06-24 04:05PM
Nov-19-24 04:05PM
Nov-14-24 04:05PM
04:05PM
Loading…
Nov-12-24 04:05PM
04:05PM
Nov-11-24 04:05PM
Nov-08-24 04:05PM
Nov-04-24 04:05PM
Nov-01-24 09:01AM
Oct-31-24 05:30PM
04:23PM
(Associated Press Finance)
04:05PM
Oct-24-24 04:05PM
Oct-22-24 04:05PM
Oct-15-24 07:10AM
Oct-14-24 07:05AM
Oct-10-24 04:05PM
Oct-09-24 05:56PM
04:05PM
Loading…
Oct-02-24 04:05PM
Oct-01-24 07:05AM
Sep-26-24 01:01PM
Sep-24-24 01:03AM
Sep-20-24 02:25AM
Sep-06-24 04:05PM
Sep-03-24 04:05PM
Aug-20-24 04:05PM
Aug-16-24 04:05PM
Aug-15-24 04:05PM
Aug-08-24 05:55PM
04:51PM
(Associated Press Finance)
04:05PM
Jul-18-24 04:05PM
Jul-10-24 01:30PM
Jul-03-24 07:37AM
Jul-02-24 09:27AM
Jul-01-24 04:05PM
Jun-12-24 05:48AM
(Pharmaceutical Technology)
May-22-24 04:25PM
May-20-24 04:05PM
May-14-24 06:00AM
May-03-24 11:14AM
06:47AM
(Thomson Reuters StreetEvents)
04:01AM
May-02-24 06:06PM
05:34PM
(Associated Press Finance)
04:05PM
Apr-18-24 04:05PM
Apr-11-24 07:05AM
Feb-29-24 10:40AM
07:08AM
(Thomson Reuters StreetEvents)
Feb-28-24 06:50PM
06:01PM
(Associated Press Finance)
04:59PM
04:05PM
Feb-26-24 04:05PM
(GlobeNewswire) +5.61%
+29.69%
08:05AM
Feb-20-24 08:05AM
Feb-14-24 04:05PM
Feb-13-24 04:05PM
Feb-01-24 04:05PM
Jan-08-24 07:03PM
Dec-27-23 08:30AM
Dec-14-23 06:45AM
(Pharmaceutical Business Review) +41.15%
Dec-13-23 04:06PM
04:05PM
Dec-11-23 07:05AM
Nov-29-23 02:46PM
Nov-28-23 04:05PM
Nov-14-23 04:05PM
(GlobeNewswire) +18.07%
+6.63%
Nov-03-23 09:14AM
(Thomson Reuters StreetEvents) +7.22%
08:58AM
Nov-02-23 06:24PM
05:04PM
(Associated Press Finance)
04:05PM
Oct-31-23 04:05PM
Oct-27-23 03:35PM
Oct-26-23 04:05PM
Oct-19-23 04:05PM
Sep-29-23 07:05AM
Sep-18-23 04:05PM
Sep-16-23 03:02PM
Sep-13-23 01:02AM
Sep-12-23 04:05PM
Sep-11-23 08:21AM
Sep-08-23 04:44PM
(American City Business Journals) +6.83%
Sep-07-23 04:05PM
Aug-24-23 09:29AM
Aug-08-23 06:00PM
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Opaleye Management Inc. 10% Owner Mar 06 '25 Buy 2.61 100,000 261,350 9,065,000 Mar 10 05:16 PM Opaleye Management Inc. 10% Owner Mar 04 '25 Buy 2.64 55,000 145,398 8,955,000 Mar 06 04:51 PM Opaleye Management Inc. 10% Owner Mar 05 '25 Buy 2.69 10,000 26,875 8,965,000 Mar 06 04:51 PM Opaleye Management Inc. 10% Owner Feb 28 '25 Buy 2.99 147,649 441,175 8,852,649 Mar 04 04:05 PM Opaleye Management Inc. 10% Owner Mar 03 '25 Buy 2.81 47,351 133,165 8,900,000 Mar 04 04:05 PM Opaleye Management Inc. 10% Owner Feb 10 '25 Buy 4.18 22,500 94,149 8,677,500 Feb 12 07:42 PM Opaleye Management Inc. 10% Owner Feb 12 '25 Buy 4.00 15,000 59,932 8,705,000 Feb 12 07:42 PM Opaleye Management Inc. 10% Owner Feb 11 '25 Buy 4.11 12,500 51,400 8,690,000 Feb 12 07:42 PM Opaleye Management Inc. 10% Owner Jan 31 '25 Buy 4.29 45,000 193,185 8,655,000 Jan 31 07:08 PM Opaleye Management Inc. 10% Owner Jan 30 '25 Buy 4.49 20,000 89,782 8,610,000 Jan 31 07:08 PM Opaleye Management Inc. 10% Owner Dec 30 '24 Buy 4.70 35,000 164,392 8,580,000 Jan 02 04:05 PM Opaleye Management Inc. 10% Owner Dec 31 '24 Buy 4.66 10,000 46,603 8,590,000 Jan 02 04:05 PM Opaleye Management Inc. 10% Owner Oct 25 '24 Buy 2.91 25,000 72,720 8,545,000 Oct 28 04:05 PM Opaleye Management Inc. 10% Owner Sep 24 '24 Buy 2.94 80,000 234,856 8,515,000 Sep 26 03:21 PM Opaleye Management Inc. 10% Owner Sep 25 '24 Buy 2.86 5,000 14,290 8,520,000 Sep 26 03:21 PM Opaleye Management Inc. 10% Owner Sep 20 '24 Buy 3.01 1,055,000 3,175,550 8,390,000 Sep 23 05:19 PM Opaleye Management Inc. 10% Owner Sep 23 '24 Buy 2.94 45,000 132,484 8,435,000 Sep 23 05:19 PM Opaleye Management Inc. 10% Owner Sep 18 '24 Buy 3.16 61,000 192,992 7,380,000 Sep 19 06:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite